ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Carl Zeiss Meditec AG's annualized return on capital (ROC %) for the quarter that ended in Dec. 2025 was 0.13%.
As of today (2026-06-24), Carl Zeiss Meditec AG's WACC % is 8.37%. Carl Zeiss Meditec AG's ROC % is 4.58% (calculated using TTM income statement data).
Carl Zeiss Meditec AG earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Carl Zeiss Meditec AG (MEX:AFXN) ROC % Explanation
ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.
There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.
Why is ROC % important?
Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, Carl Zeiss Meditec AG's WACC % is 8.37%. Carl Zeiss Meditec AG's ROC % is 4.58% (calculated using TTM income statement data).
Carl Zeiss Meditec AG earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Be Aware
Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note:
The Operating Income data used here is four times the quarterly (Dec. 2025) data.
The tax rate is limited to between 0% and 100%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Carl Zeiss Meditec AG (MEX:AFXN) has a ROC % of 0.13% as of Dec. 2025. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Carl Zeiss Meditec AG and its competitors.
Is Carl Zeiss Meditec AG's ROC % too high?
Carl Zeiss Meditec AG's current ROC % is 0.13%. The Medical Devices & Instruments industry median ROC % is 1.27. Carl Zeiss Meditec AG's value of 0.13% is 89.8% below this industry median. Overall, Carl Zeiss Meditec AG has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Carl Zeiss Meditec AG's ROC % compare to ISRG and BDX?
Carl Zeiss Meditec AG's ROC % of 0.13% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROC % is 1.27. Carl Zeiss Meditec AG's value of 0.13% is 89.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Medical Devices & Instruments company?
The median ROC % among Medical Devices & Instruments companies is 1.27, based on 847 companies in the industry. Companies in the top quartile (top 25%) have a ROC % significantly above this median, while those in the bottom quartile fall well below. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Carl Zeiss Meditec AG's current ROC % of 0.13% is 89.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Carl Zeiss Meditec AG and its competitors. For the Medical Devices & Instruments industry, the median ROC % is 1.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Carl Zeiss Meditec AG's current ROC % is 0.13%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carl Zeiss Meditec AG stock overvalued right now?
Carl Zeiss Meditec AG (MEX:AFXN) has a current ROC % of 0.13%. The stock's GF Value™ is MXN8,900.18, compared to a current price of MXN3,258.20 — trading 63.4% below its estimated fair value. The current ROC % is 0.13% and 89.8% below the Medical Devices & Instruments industry median of 1.27. Carl Zeiss Meditec AG's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Carl Zeiss Meditec AG (MEX:AFXN), the current ROC % is 0.13% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Carl Zeiss Meditec AG (MEX:AFXN) Overvalued in 2026?
Based on GuruFocus' analysis, Carl Zeiss Meditec AG stock appears to be undervalued.
The current stock price of MXN3,258.20 is trading 63.4% below its estimated GF Value™ of MXN8,900.18.
Key valuation signals for MEX:AFXN:
ROC %: 0.13%
GF Value™: MXN8,900.18 vs. price of MXN3,258.20 (63.4% below fair value)
Industry Position: 89.8% below the Medical Devices & Instruments median
No single metric tells the full story. See the MEX:AFXN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up about 75% of sales in 2025, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
68GF Score
Get the complete analysis for MEX:AFXN
ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:AFXN has been successfully added to your 
